Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

Core Insights - Novo Nordisk has launched the first GLP-1 pill for weight loss in the U.S., marking a significant advancement in obesity treatment [1] Group 1: Product Launch - The new obesity medicine from Novo Nordisk is now available in pill form, expanding treatment options for patients [1] - This launch represents a major milestone as it is the first oral GLP-1 medication approved for weight loss in the U.S. [1] Group 2: Market Impact - The introduction of the pill is expected to enhance accessibility for patients who may prefer oral medications over injections [1] - This development could potentially increase the market share of Novo Nordisk in the obesity treatment sector [1]